Premium
Biotransformation
Author(s) -
Ito S
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.133
Subject(s) - clinical pharmacology , clinical trial , medicine , drug development , human immunodeficiency virus (hiv) , drug , intensive care medicine , pharmaceutical industry , public health , pharmacology , virology , pathology
Because the threat of infectious diseases can cause widespread fear in a community, these diseases receive much public attention. Collaborations that bring together industry, academia, regulators, and the public can lead to improved and accelerated drug development. The collaborations must be grounded in strong science and expertise in clinical trials. Development of drugs to treat infections caused by resistant bacteria, drugs to treat hepatitis C virus (HCV), and drugs to prevent HIV is taking advantage of these collaborations. Clinical Pharmacology & Therapeutics (2014); 96 3, 281–283. doi: 10.1038/clpt.2014.133